Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part and have signed a consent form agreeing to join the study
• People aged 18 to 74 years old (any gender)
• People whose general physical health is rated as fully active or able to carry out light work, based on a standard medical scoring system called ECOG (scores 0 or 1)
• People whose doctors expect them to live for at least 12 months
• People who have been confirmed by tissue testing to have a type of lung cancer called non-small cell lung cancer (NSCLC) that is located in the outer part of the lung, at a stage between IIA and IIIB (using IASLC 9th edition staging), and whose cancer does not have certain genetic changes known as EGFR mutations or ALK rearrangements
• People whose cancer is contained within a single section (lobe) of the lung, with no solid tumours spread across different lobes
• People who have not had open chest surgery on the same side of the chest before
• People who have already completed 2 to 4 cycles of pre-surgery treatment (called neoadjuvant therapy) involving both an immunotherapy drug (a PD-1 or PD-L1 inhibitor) and a two-drug platinum-based chemotherapy combination
• People whose heart and lung function is considered sufficient for surgery, including specific breathing test results (FEV1 of at least 1.5 L or a lung gas exchange measure called DLCO of at least 40%), as assessed by the treating doctor
• People whose tumour is more than 2 cm away from the airway opening, based on a pre-surgery CT scan
• People whose tumour has been assessed by a review committee as suitable for a specific type of lung surgery that removes less than a full lobe, while completely removing the cancer (called sub-lobe R0 resection)

Who may not be able to join:

• People who are not expected to tolerate a full lobe removal surgery (lobectomy)
• People who have received radiation therapy to the chest before the planned surgery
• People who have had a transplant of donated tissue or a solid organ (such as a kidney or liver)
• People who have been diagnosed with an autoimmune disease, or who have been taking steroid medication (such as prednisone at more than 10 mg per day) or other immune-suppressing treatments within the 3 months before surgery
• People who have a history of a non-infectious lung scarring condition (interstitial lung disease) that has required steroid treatment, or who currently have this condition and need steroid treatment for it
• People who test positive for HIV, or who have active hepatitis B or active hepatitis C, based on blood tests done during the screening period
• People with high blood pressure that is not well controlled by medication, meaning blood pressure readings remain above 150/90 mmHg on average across the three most recent measurements taken before joining the study
• People who have an active infection during the screening period that still requires intravenous (drip) antibiotic or antiviral treatment
• People who have had another cancer (other than certain low-risk or fully treated cancers such as skin basal cell cancer, cervical or breast cancer in situ, superficial bladder cancer, or localised prostate cancer) within the 3 years before signing the consent form — though people with low-risk early prostate cancer under stable active monitoring or who have received curative treatment may still be considered eligible (confirm with trial site)
• People whose situation, in the treating doctor's judgement, could interfere with the study results or for whom participation would not be in their best interest
• People who are pregnant, breastfeeding, or planning to become pregnant, or who have a positive pregnancy blood test within 7 days before starting the study treatment
• People who are unlikely to follow the study procedures or are unwilling or unable to complete the full study process

Important: Always verify eligibility with the trial site directly before applying.